Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Information about the Annual Report 2022/23

Diamyd Medical today publishes the Annual Report for 2022/23 in Swedish and announces the following change in the Annual Report compared to the Year-end Report, which was published on October 11, 2023.Diamyd Medical's partnership with JDRF[*] means that JDRF contributes with financial   support. Payments from JDRF are earned when Diamyd Medical completes various milestones in the DIAGNODE-3 study, with these milestones spanning the years 2023 - 2027. JDRF can also use its global type 1 diabetes network to raise awareness of the study, which may contribute to patient recruitment, and also

TORM purchases eight LR2 vessels

On 09 November 2023, TORM has entered into an agreement to acquire eight second-hand LR2 vessels that are expected to be delivered in late Q4 2023 and in Q1 2024 for a total consideration of USD 399m, with a cash consideration of USD 239m and the issuance of approximately 5.5 million shares (1). The purchase price is subject to certain adjustments that will be impacted by TORM’s share price development and the vessels’ delivery schedules.   The vessels have all been built at the Tier 1-Korean yard Hyundai Samho Heavy Industries in 2010-2012 and have fuel-efficient eco vessel

Rejlers at top 5 when Sweden's Best Employer is appointed by employees

When the results of Sweden's Best Employer 2023 were released today, Rejlers placed fifth in the Large Employers category. A characteristic feature of the ranking, which is conducted annually by the Employer Branding company Universum, is that the company's own employees rate their employer. In this year's ranking, Rejlers also retains first place as the technology consulting industry's best employer, for the third year in a row.When Rejlers' employees are asked what makes the company an attractive place to work, there are several things that are highly valued: great variety in assignments

Imfinzi combination improves PFS in liver cancer

09 November 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial First global Phase III trial to show improved clinical outcome for systemic therapyin combination with transarterial chemoembolisation (TACE) in this setting Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in

Non-Executive Director Appointment and Lancashire Board Chair Succession Planning

LANCASHIRE HOLDINGS LIMITED 9th November 2023 Hamilton, Bermuda Lancashire Holdings Limited (“Lancashire”/“LHL”) - Non-Executive Director Appointment and Lancashire Board Chair Succession Planning Lancashire announces the appointment of Philip Broadley as a Non-Executive Director of LHL with effect from 8 November 2023.  Mr Broadley has also been appointed as the LHL Chair designate, and Lancashire expects his appointment as Chair to take effect immediately following Lancashire’s 2024 AGM to be held on 1 May 2024 (“the 2024 AGM”), subject to shareholder approval. Peter Clarke,

Agreement with Eccogene for clinical stage GLP-1RA

09 November 2023 AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Global rights to Eccogene's next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating

Anora’s financial reporting and Annual General Meeting in 2024

Anora Group Plc   Stock Exchange Release   9 November 2023 at 9:00 a.m. EET Anora’s financial reporting and Annual General Meeting in 2024 Anora will publish financial reports in 2024 as follows: 14 February 2024: Financial Statements Bulletin for 2023 7 May 2024: Interim Report for January-March 2024 20 August 2024: Half-Year Report for January-June 2024 7 November 2024: Interim Report for January-September 2024 These financial reports will be published at approximately 8:30 a.m. Finnish time. Anora applies a silent period of 30 days before the publication of financial

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are satisfied with the encouraging disease control rate achieved in late stage and heavily pretreated melanoma patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial potential that could be

Quickbit signs its first customer on Abicart's e-commerce platform

Today, Quickbit announces that the first customer on Abicart's e-commerce platform has been signed. This marks the initial step in Quickbit's strategic collaboration with Abicart, providing Quickbit access to a large and growing network of merchants.In early November 2023, Quickbit entered into a cooperation agreement with the e-commerce platform Abicart. This collaboration grants Quickbit access to an extensive network of merchants, totaling approximately 2500. Now, Quickbit signs its first merchant through the platform – a vendor of locks and security products. The merchant has

Interim report January – September 2023

CONTINUED STRONG PROFIT – INCREASED VOLUMESJuly – September 2023 · Sales volume amounted to 4,819 tonnes (3,817 tonnes) an increase by 26%. · Net sales amounted to SEK 262.9 million (SEK 232.0 million), an increase by 13%. The organic increase was 5%. · Operating profit amounted to SEK 28.0 million (SEK 10.8 million), an increase by 159%. · The operating margin increased to 10.7% (4.7%) · Profit for the period amounted to SEK 20.8 million (SEK 7.6 million), an increase by 174%. · Earnings per share before dilution amounted to SEK 1.03 (SEK 0.38) and after dilution to SEK

Michel Thomas is the new CEO for Qarlbo Energy

Press releaseStockholm, November 9 Michel Thomas has been appointed as the new CEO of Qarlbo Energy. Most recently he comes from EON where he for fifteen years held various roles, both nationally and internationally."Michel has a deep understanding of driving business and growth in a rapidly changing energy market. He has worked across the entire value chain – from large-scale power generation and energy distribution to customer solutions and sales. With his experience, Qarlbo Energy can become a leading player in the energy transition”, says Pär Nuder, chairman of the board of Qarlbo

Acroud publishes interim report Jul-Sept 2023: Stronger balance sheet, reduced debt and improved cash-flows

Financial highlights during third quarter 2023 · Revenue amounted to EUR 9 868 (6 683) thousand, corresponding to a growth of 48% and an organic revenue growth of -16.5%. · Adjusted EBITDA (before items affecting comparability) was EUR 1 175 (1 496) thousand decreasing by 21% year-on-year.  EBITDA amounted to EUR 945 (1 496) thousand, decreasing by 37% year-on-year. · Profit after tax was EUR -1 874 (-589) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR -753 (-188) thousand. · Earnings per share after dilution amounted to

Interim Report January–September 2023

John Mattson is strengthening the company for the futureThe surplus ratio for the January to September 2023 period amounted to 72%, a record high for the company. Net operating income increased 7% and, year-on-year, EBITDA increased 11%. This was despite a smaller property portfolio following completed sales as well as continued high inflation and non-recurring costs during the second quarter. As a result of rising market interest rates during the period, income from property management declined 28% per share compared with the year-earlier period. The change in value was a decrease of 2.

Q3 Trading Statement

LANCASHIRE HOLDINGS LIMITED 9 November 2023 Hamilton, Bermuda Lancashire Holdings Limited (“Lancashire” or “the Group”) today announces its trading statement for the nine  months ended 30 September 2023. Trading statement highlights · Gross premiums written increased by 23.2% year-on-year to $1.6 billion. · IFRS 17 insurance revenue increased by 22.1% year-on-year to $1.1 billion. · Group Renewal Price Index (RPI) of 117%. · Total net investment return, including unrealised gains and losses, of 2.8%. · Capital return of up to $169 million ($119 million

Interim Report Third Quarter 2023

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2023 – 30.09.2023. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:” Stenocare has successfully managed to grow sales to patients during the first three quarters of 2023. We have proven our strategic assets and are very optimistic about the road ahead.” (KDKK)

Peab builds more apartments in Umeå

Peab has already completed construction of seven apartment buildings at Mariehöjd in Umeå and is now beginning on the eighth stage which will comprise 79 tenant-owner apartments and two common areas. The customer is Mariehöjd Produktion and the contract is worth SEK 133 million.Peab bought the property in 2011 and began planning a new city borough at Mariehöjd in Umeå. We are now starting on the eighth of nine planned stages, commissioned by Mariehöjd Produktion which is a company jointly owned by HSB Norr and Peab Bostad. In addition to the 79 apartments there will be two common areas

Nomination Committee appointed for MSAB´s Annual General Meeting 2024

In accordance with the decision by the Annual General Meeting, MSAB´s Nomination Committee shall consist of three members. The members should be one representative of each of the three largest shareholders in terms of voting rights that wish to participate in the committee. Furthermore, if necessary, MSAB´s Chairperson of the MSAB board shall be co-opted at the meetings of the Nomination Committee.This year’s Nomination Committee consists of the following members: Erik Ivarsson (AB Grenspecialisten) Christian Hellman (Edastra AB) David Zaudy (Cervantes Capital AB) Erik Ivarsson

Everysport Group (publ) publishes interim report for Q3 2023: Strengthened balance sheet and position for long-term growth

Summary of the third quarter 2023: · Net sales SEK 36.5 million (43.3) · Adjusted EBITDA SEK 3.2 million (3.2) · EBITDA SEK 43.1 million (3.2) · Adjusted EBIT SEK -2.8 million (-10.7) · Profit after financial items SEK 17.4 million (-12.6) · Earnings per share SEK 2.81 (-1.73) Summary January to September 2023: · Net sales SEK 117.8 million (141.0) · Adjusted EBITDA SEK 11.2 million (10.0) · EBITDA SEK 50.2 million (10.0) · Adjusted EBIT SEK -10.2 million (-27.1) · Result after financial items SEK -0.2 million (-32.7) · Earnings per share SEK -0.06

Welcome to Wärtsilä’s Capital Markets Day 2023

Wärtsilä Corporation, Press release, 9 November 2023 at 09.00 EETWärtsilä hosts a Capital Markets Day for investors, analysts, and representatives from banks and media today at 13:00–16:30 EET. During the event, Wärtsilä’s President & CEO Håkan Agnevall together with members of the Board of Management will provide information on the company's business environment, the strategic themes of Transform and Perform, and the roadmap to reach the reconfirmed financial targets. “We have seen good progress on our journey of shaping the decarbonisation of the marine and energy industries. Our focus

MEKO invests in a new high-technology warehouse in Norway

MEKO is increasing its focus on the Norwegian market and investing in a new fully automated central warehouse in Oslo. The new facility will consolidate MEKO's inventory management in Norway and is expected to provide lasting cost savings and improved service. The warehouse is anticipated to be fully operational by the end of 2025.MEKO is a leader in the independent automotive aftermarket in Norway through its business areas Sörensen og Balchen and Sweden/Norway, which include the MECA and Mekonomen brands. Until now, merchandise handling for these operations has taken place in separate

Interim report Quartiers Properties January - September 2023

Quartiers Properties AB (publ) today publishes the company's interim report for the third quarter of 2023.JULY - SEPTEMBER 2023 · Revenue from operator activities totalled KSEK 41,164 (38,166), including KSEK 37,100 for Boho Club, which thus increased its revenue compared with the corresponding period in 2022 by 27.2%. Other income from operator activities refers to the rental operation at Quartiers Marbella Apartments. · Net sales totalled KSEK 64,104 (78,385), corresponding to a decrease of 18.2%. The decrease can be attributed to fewer apartments sold during the quarter compared

Stayble Therapeutics reports top-line data from the company's phase IIb study

Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc disease, "DDD". The randomized, double-blind study did not meet the primary objective. According to the pre-specified statistical criteria, STA363 compared to placebo did not show a statistically significant reduction in pain at six months.The study was a randomized, double-blind, placebo-controlled concept study investigating the efficacy and safety of two concentrations of STA363 (60 and 120 mg/ml) compared to placebo in

Neogap raises SEK 83 million for a clinical phase I/II cancer study

The Swedish biotechnology company Neogap Therapeutics announces that the company has raised SEK 54 million in a new share issue and has also been granted an additional SEK 29 million in innovation funding from the EU. The total capital injection will be allocated to the company's ongoing clinical phase I/II study of patients with colorectal cancer and preparations for the subsequent study.Neogap Therapeutics, a company developing cell therapy for personalised cancer treatment, has strengthened its financial position through a new share issue of SEK 54 million, before issue costs, with the

There are no items matching the current filter
There are no more items matching the current filter
Back to top